NVHR Welcomes New Hepatitis B Vaccine

Share this


NVHR today welcomed the U.S. Food and Drug Administration’s (FDA) approval of HEPLISAV-B for prevention of hepatitis B virus infection in adults ages 18 and older. HEPLISAV-B is the first new hepatitis B vaccine approved in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.